- Home
- RITM vs LEGN Comparison
RITM vs LEGN Comparison
Compare RITM & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RITM
- LEGN
- Stock Information
- Founded
- RITM 2011
- LEGN 2014
- Country
- RITM United States
- LEGN United States
- Employees
- RITM N/A
- LEGN N/A
- Industry
- RITM Real Estate Investment Trusts
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- RITM Real Estate
- LEGN Health Care
- Exchange
- RITM Nasdaq
- LEGN Nasdaq
- Market Cap
- RITM 6.1B
- LEGN 5.9B
- IPO Year
- RITM N/A
- LEGN 2020
- Fundamental
- Price
- RITM $11.10
- LEGN $30.33
- Analyst Decision
- RITM Strong Buy
- LEGN Strong Buy
- Analyst Count
- RITM 8
- LEGN 13
- Target Price
- RITM $14.25
- LEGN $72.92
- AVG Volume (30 Days)
- RITM 6.6M
- LEGN 1.3M
- Earning Date
- RITM 10-30-2025
- LEGN 11-12-2025
- Dividend Yield
- RITM 8.99%
- LEGN N/A
- EPS Growth
- RITM 46.96
- LEGN N/A
- EPS
- RITM 1.45
- LEGN N/A
- Revenue
- RITM $3,961,432,000.00
- LEGN $909,045,000.00
- Revenue This Year
- RITM N/A
- LEGN $68.68
- Revenue Next Year
- RITM $4.75
- LEGN $48.49
- P/E Ratio
- RITM $7.67
- LEGN N/A
- Revenue Growth
- RITM 32.03
- LEGN 74.75
- 52 Week Low
- RITM $9.13
- LEGN $27.34
- 52 Week High
- RITM $12.74
- LEGN $45.30
- Technical
- Relative Strength Index (RSI)
- RITM 50.28
- LEGN 33.91
- Support Level
- RITM $10.82
- LEGN $29.92
- Resistance Level
- RITM $11.31
- LEGN $33.50
- Average True Range (ATR)
- RITM 0.19
- LEGN 1.33
- MACD
- RITM 0.05
- LEGN -0.10
- Stochastic Oscillator
- RITM 65.72
- LEGN 10.89
About RITM Rithm Capital Corp.
Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company aims to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Its investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights) loans (including single-family rental), and consumer loans. Its operating segments are Origination and Servicing; Investment Portfolio; Residential Transitional Lending; and Asset Management.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.